Pharmacology - OPIOIDS (MADE EASY)

Main Ideas & Concepts

What Opioids Are

• Opioids (also called narcotics) are drugs that act on the central nervous system.
• They produce morphine-like effects, including:
  • Pain relief (analgesia)
  • Euphoria

How Pain Transmission Works (Baseline Physiology)

• Pain starts at nociceptors: branching endings of sensory neurons in the peripheral nervous system.
• These are high-threshold primary sensory neurons that detect body damage and transmit pain to:
  • Second-order neurons in the dorsal horn of the spinal cord.
• The signal then travels through the spinothalamic tract → thalamus → somatosensory cortex, where pain is perceived.
• At the microscopic level, pain is encoded as:
  • Repeated action potentials
  • The firing frequency depends on pain intensity.

Key Neurotransmitters Involved in Pain Signaling

• Presynaptic release into synaptic clefts includes:
  • Glutamate
  • Substance P
  • Calcitonin gene-related peptide (CGRP)

How These Neurotransmitters Increase and Propagate Pain

• Glutamate

  • Activates AMPA and NMDA receptors.
  • Causes influx of positively charged ions:
    • Na⁺ via AMPA
    • Ca²⁺ via NMDA
  • Increased positive ion flow makes neurons more likely to fire, supporting propagation of a sharp, localized pain signal.

• Substance P

  • Binds NK-1 (neurokinin-1) receptors.
  • Triggers intracellular pathways involving:
    • arachidonic acid pathways
    • nitric oxide synthesis
    • NMDA receptor activation
  • Mechanistic detail described:
    • Substance P interaction leads to PKC activation and removal of Mg²⁺ block from NMDA receptors
    • This allows glutamate to bind NMDA receptors → Ca²⁺ influx → pain increases and fires more frequently

• CGRP

  • Binds CGRP receptors on second-order neurons.
  • Alters receptor expression/function, changing neuronal activity.
  • Contributes to central sensitization, characterized by:
    • lowered threshold to evoke action potentials

How the Body Naturally Counteracts Pain

• The body releases endogenous opioids.
• Three major families:
  • Enkephalins
  • Dynorphins
  • Endorphins
• These bind opioid receptors present in both the central and peripheral nervous systems.

Opioid Receptor Types and General Mechanism

• Three major opioid receptors:
  • µ (mu)
  • δ (delta)
  • κ (kappa)
• Differences (as stated):
  • cellular distribution
  • relative affinity for opioid ligands
  • effects produced
• All are described as:
  • 7-transmembrane proteins
  • coupled to inhibitory G-proteins
• They are present in high concentrations in the dorsal horn of the spinal cord.

What Receptor Activation Does to Neural Signaling

• When opioid receptors are activated (example given: endogenous µ-opioid peptide endorphin):
  • Closing voltage-gated Ca²⁺ channels on presynaptic terminals → less neurotransmitter release (glutamate, Substance P, CGRP)
  • Opening K⁺ channels → K⁺ efflux
  • Results in hyperpolarization, making neurons less sensitive to excitation

---

Opioid Analgesics (Drug Examples and Special Note)

General Rule

• Most opioid analgesics primarily act at µ-opioid receptors, mimicking endogenous opioid peptide effects.

Synthetic Opioid Agonists Mentioned

• Fentanyl
• Hydrocodone
• Hydromorphone
• Methadone
• Meperidine
• Oxycodone
• Oxymorphone

Methadone Special Properties (Highlighted)

• Not only a strong µ receptor agonist
• Also described as:
  • NMDA receptor antagonist
  • norepinephrine reuptake inhibitor
  • serotonin reuptake inhibitor
• Claimed benefit from these properties:
  • useful for nociceptive and neuropathic pain

---

Side Effects (Main Adverse Effects Explained)

Nausea

• Caused by direct stimulation of the chemoreceptor trigger zone in the medulla.

Respiratory Depression (Dose-Dependent)

• Due to reduced responsiveness of brainstem respiratory centers to CO₂
• Also depresses respiratory centers in the pons and medulla that regulate respiratory rhythmicity.

Antitussive Effect

• Opioids suppress the cough center in the medulla.

Immune Suppression

• Opioids suppress immunity because opioid receptors regulate immune processes.

Histamine-Related Cardiovascular Effects

• Morphine and Meperidine may provoke histamine release
• Histamine contributes to hypotension
• Injection of Morphine/Meperidine can cause cutaneous vasodilation → flushing (face/neck/upper thorax)

Heart Rate Effects

• Meperidine: tachycardia attributed to structural similarity to Atropine
• Other opioids: dose-dependent bradycardia via centrally mediated vagal stimulation

Other Common Effects

• Itching (pruritus): central action on pruritoceptive circuits
• Constipation:
  • decreased gastric motility
  • prolonged gastric emptying
• Urinary retention:
  • decreased renal function
  • antidiuretic effects
  • increased sphincter tone

---

Addiction & Withdrawal (Mechanism Overview)

Why Opioids Cause Addiction

• Addiction involves physical and psychological dependence.
• Euphoria/reward mechanism described:
  • involves GABA-inhibitory interneurons of the ventral tegmental area (VTA)
  • Normally, GABA reduces dopamine release in the nucleus accumbens (pleasure/reward system)
  • Opioids activate µ receptors in that area → suppresses GABA release
  • This increases dopamine activity → increased pleasure

Tolerance and Receptor Adaptations

• Prolonged use → desensitization and down-regulation of receptor signaling
• When opioids are reduced/stopped → withdrawal symptoms

Withdrawal as the “Opposite” of Drug Effects

• Respiratory/GI and cardiovascular shifts:
  • instead of decreased respiration → diarrhea
  • instead of slowing respiration → elevated blood pressure
• Mood shifts:
  • instead of pleasure → increased dysphoria and anxiety via reinforcement involving the nucleus accumbens and amygdala
• Escalation loop:
  • negativity feeds into the prefrontal cortex, increasing desire for opioids

---

Pharmacologic Agents Interacting with Opioid Receptors (Contrasting Roles)

1) Buprenorphine (Partial µ Agonist)

• Type
  • Partial µ receptor agonist
• Mechanism described
  • Full agonist:
    • binds µ receptor and induces a full receptor response via shape change
  • Partial agonist (Buprenorphine):
    • smaller shape change → partial response
  • Effects rise only until a plateau
• Effects and clinical implication (as stated)
  • Can cause respiratory depression and euphoria
  • But maximal effects are smaller than full agonists
  • Benefits claimed:
    • lower risk of abuse
    • lower risk of addiction
    • fewer side effects
• Additional receptor activity
  • Buprenorphine is also described as:
    • antagonist at δ and κ receptors
  • Contribution of these to analgesia:
    • stated as currently unclear

2) Naloxone (Opioid Antagonist)

• Type
  • Opioid antagonist to block/reverse opioid effects
• Mechanism described
  • Has stronger affinity for opioid receptors
  • “Knocks off” opioids already attached to receptors
  • Temporarily stops opioid effects by preventing re-attachment
• Emergency use
  • Used when opioid overdose causes slowed/stopped breathing
  • Can quickly restore normal breathing and save lives

---

Speakers / Sources Featured

• No specific speaker name is provided in the subtitles.
• Only referenced biological targets/brain regions and drugs (no external human sources named).